Source: Fertility and Sterility. Conference titles: Scientific Congress of the American Society for Reproductive Medicine. Unidade: FMRP
Subjects: MUTAÇÃO GENÉTICA, QUIMIOTERAPIA, AMENORREIA, NEOPLASIAS MAMÁRIAS
ABNT
OKTAY, Kutluk H. et al. Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2ng/ml strongly predict risk of amenorrhea in women with breast cancer. Fertility and Sterility. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.fertnstert.2022.08.652. Acesso em: 24 abr. 2026. , 2022APA
Oktay, K. H., Turan, V., Bedoschi, G. M., Goldfarb, S. B., & Bang, H. (2022). Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2ng/ml strongly predict risk of amenorrhea in women with breast cancer. Fertility and Sterility. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.fertnstert.2022.08.652NLM
Oktay KH, Turan V, Bedoschi GM, Goldfarb SB, Bang H. Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2ng/ml strongly predict risk of amenorrhea in women with breast cancer [Internet]. Fertility and Sterility. 2022 ; 118( 4S): e231.[citado 2026 abr. 24 ] Available from: https://doi.org/10.1016/j.fertnstert.2022.08.652Vancouver
Oktay KH, Turan V, Bedoschi GM, Goldfarb SB, Bang H. Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2ng/ml strongly predict risk of amenorrhea in women with breast cancer [Internet]. Fertility and Sterility. 2022 ; 118( 4S): e231.[citado 2026 abr. 24 ] Available from: https://doi.org/10.1016/j.fertnstert.2022.08.652
